Chng Wee Joo, MB, ChB, PhD, FRCP, FRCPath, FAMS from the National University Cancer Institute, Singapore gives an overview of his talk on the utility of next-generation sequencing (NGS) in multiple myeloma (MM) held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. According to Prof Chng, a lot of progress has been made in NGS but its clinical use in MM is not well established yet. There is great potential in helping to target treatment and understanding prognosis as well as drug resistance. Further, a key point of the talk was how to identify high-risk patients and to design clinical trials for this group of patients.